Laekna Therapeutics Doses First Patient in LAE001/LAE002 Study for Prostate Cancer
China-based Laekna Therapeutics Shanghai Co., Ltd announced that the first patient has been dosed in...
NHSA Reveals Drugs Passing Initial Review for NRDL Inclusion
The National Healthcare Security Administration (NHSA) released a notification listing the drugs that have passed...
Innovent’s Tyvyt Combo Shows PFS Benefit in EGFR-Mutant NSCLC
China-based Innovent Biologics Inc. (HKG: 1801) announced positive results from the Phase III ORIENT-31 study...
Huadong Medicine Pays EUR 105M for 35% Stake in Heidelberg Pharma
China’s Huadong Medicine Co., Ltd (SHE: 000963) announced that it has paid a total of...
CStone Pharmaceuticals Partners with Rigen Biotech on Thyroid Cancer RET Gene Testing
China-based CStone Pharmaceuticals (HKG: 2616) has entered into a partnership with Shanghai Rigen Biotech to...
Biocytogen and FineImmune Partner on Innovative Cell Therapy Drug Development
China-based Contract Research Organization (CRO) Biocytogen (Beijing) Co., Ltd has entered into a collaboration with...
CMS’s Rxilient Medical Licenses Insulin Products from Hefei Tianmai Biotech
China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd...
Kelun Pharmaceutical Receives USD 35 Million from Merck Sharp & Dohme Corp.
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that it has received a USD...
Hainan Yuekang’s YK-029A Biosimilar Set for BTD in EGFR ex20ins NSCLC
The Center for Drug Evaluation (CDE) website indicates that China-based Hainan Yuekang Biological Medicine Co.,...
Walvax Biotech Enrolls First Subject in Phase III HPV Vaccine Study
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced the first subject enrollment for a Phase...
Sinocelltech’s Ripertamab Officially Launched in China for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced the first deliveries and prescriptions of its ripertamab...
Innovent’s Tyvyt Shows PFS Benefit in EGFR-Mutant NSCLC at ESMO
China-based Innovent Biologics, Inc. (HKG: 1801) presented results of the ORIENT-31 study for its PD-1...
Luye Pharma’s CD25 Monoclonal Antibody BA1106 Gains NMPA Approval for Clinical Trials
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...
Fosun Pharma Inks Licensing Deal with Neovii for GvHD Therapy Grafalon
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) signed an exclusive licensing...
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
HutchMed’s Elunate Shows Survival Benefit in Global CRC Study at ESMO
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the results of the pivotal...
Jacobio’s KRAS G12C Inhibitor JAB-21822 Advances to Pivotal Phase II in NSCLC
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has received approval from the National Medical...
Lianren Digital Health Partners with Ningbo Government on Health Data Ecosystem
Shanghai-based Lianren Digital Health has forged a strategic partnership with the People’s Government of Ningbo...
Bio-Heart Invests RMB 50M in Cardiotek to Advance Balloon-Expandable TAVR Device
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese interventional cardiovascular device maker,...
HitGen’s Vernalis Subsidiary Collaborates with Unison Medicines on Undruggable Bacterial Target
China’s HitGen Inc. (SHA: 688222) announced a strategic research collaboration between its wholly owned subsidiary,...